tiprankstipranks
Advertisement
Advertisement
Qualcomm upgrade, Intel initiation among today’s top calls on Wall Street
PremiumThe FlyQualcomm upgrade, Intel initiation among today’s top calls on Wall Street
14d ago
Exelixis assumed with Hold from Buy at Truist
Premium
The Fly
Exelixis assumed with Hold from Buy at Truist
14d ago
Exelixis Colorectal Cancer Data Underwhelms: Gerberry Maintains Sell/Underperform with Price Target Below Current Share Price
Premium
Ratings
Exelixis Colorectal Cancer Data Underwhelms: Gerberry Maintains Sell/Underperform with Price Target Below Current Share Price
16d ago
Exelixis announces clinical development collaboration with Merck
PremiumThe FlyExelixis announces clinical development collaboration with Merck
2M ago
Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion
Premium
Company Announcements
Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion
2M ago
Exelixis price target raised to $56 from $54 at H.C. Wainwright
Premium
The Fly
Exelixis price target raised to $56 from $54 at H.C. Wainwright
2M ago
Exelixis Kept at Hold as Cabo Momentum Offsets Pipeline Uncertainty; Price Target Raised from $49 to $50
PremiumRatingsExelixis Kept at Hold as Cabo Momentum Offsets Pipeline Uncertainty; Price Target Raised from $49 to $50
2M ago
Exelixis Price Target Raised to $55 on Cabo Strength, Buyback-Driven EPS Growth, and Zanzalintinib Upside Optionality
Premium
Ratings
Exelixis Price Target Raised to $55 on Cabo Strength, Buyback-Driven EPS Growth, and Zanzalintinib Upside Optionality
2M ago
Analyst Reiterates Buy on Exelixis, Citing STELLAR-304 Momentum, Cabometyx Durability, and Share Repurchases
Premium
Ratings
Analyst Reiterates Buy on Exelixis, Citing STELLAR-304 Momentum, Cabometyx Durability, and Share Repurchases
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100